LEETRO
430425
Geovis Insighter Technology
920116
Beijing Global Safety Technology
300523
4
Zhejiang JW Precision Machinery
300984
5
Wintao Communications
301139
CN Stock MarketDetailed Quotes
600645 Vcanbio Cell & Gene Engineering Corp.,Ltd.
- 20.90
- -0.36-1.69%
Market Closed Mar 5 15:00 CST
9.78BMarket Cap90.87P/E (TTM)
21.30High20.75Low75.34KlotVolume21.26Open21.26Pre Close157.43MTurnover1.61%Turnover Ratio92.07P/E (Static)467.95MShares24.0852wk High2.70P/B9.78BFloat Cap15.0552wk Low23.39Limit Up467.77MShs Float79.58Historical High19.13Limit Down2.59%Amplitude1.23Historical Low--Dividend TTM20.90Avg Price49.56KlotAsk--Div YieldTTM100Lot Size23.18KlotBid
Vcanbio Cell & Gene Engineering Corp.,Ltd. News
Zhongyuan Concord: Announcement of Zhongyuan Concord Cytogenetic Engineering Co., Ltd. on the signing of a property service entrustment contract and related transactions between the holding subsidiary and Tianjin Hung Hom Property Management Co., Ltd.
Announcement of Zhongyuan Xiehe Cell Genetic Engineering Co., Ltd. on the signing of a property service entrustment contract and related transactions between the holding subsidiary and Tianjin Hung Hom Property Management Co., Ltd.
Announcement of Zhongyuan Xiehe Cytogenetic Engineering Co., Ltd. on obtaining a notice of acceptance of the wholly-owned subsidiary\'s drug clinical trial application
Zhongyuan Xiehe: Announcement of Zhongyuan Xiehe Cytogenetic Engineering Co., Ltd. on the use of temporarily idle funds raised and own funds for cash management
Announcement of Zhongyuan Xiehe Cell Genetic Engineering Co., Ltd. on the use of temporarily idle funds raised and own funds for cash management
Announcement of Zhongyuan Xiehe Cytogenetic Engineering Co., Ltd. on the wholly-owned subsidiary obtaining a notice of approval for drug clinical trials
Announcement of Zhongyuan Xiehe Cytogenetic Engineering Co., Ltd. on the progress of wholly-owned subsidiary drug clinical trials and obtaining US FDA orphan drug qualification
Zhongyuan Kyowa: Announcement of Resolutions of the 2024 Second Extraordinary General Meeting of Shareholders of Zhongyuan Xiehe Cytogenetic Engineering Co., Ltd.
Zhongyuan Xiehe: Legal Opinion of Beijing Guofeng Law Firm on the 2024 Second Extraordinary General Meeting of Shareholders of Zhongyuan Xiehe Cell Genetic Engineering Co., Ltd.
Legal Opinion of Beijing Guofeng Law Firm on the 2024 Second Extraordinary General Meeting of Shareholders of Zhongyuan Xiehe Cytogenetic Engineering Co., Ltd.
Announcement of Resolutions of the 2024 Second Extraordinary General Meeting of Shareholders of Zhongyuan Xiehe Cytogenetic Engineering Co., Ltd.
An indicative announcement of Zhongyuan Xiehe Cytogenetic Engineering Co., Ltd. on convening the 2nd Extraordinary General Meeting of Shareholders in 2024
Zhongyuan Xiehe Cytogenetic Engineering Co., Ltd. 2024 Second Extraordinary General Meeting of Shareholders Meeting Data
Revised Constitution of Zhongyuan Xiehe Cell Genetic Engineering Co., Ltd.
Announcement of Zhongyuan Xiehe Cell Genetic Engineering Co., Ltd. on changing the scope of business and amending the company\'s articles of association
Notice of Zhongyuan Xiehe Cell Genetic Engineering Co., Ltd. on convening the 2nd Extraordinary General Meeting of Shareholders in 2024
Announcement of Zhongyuan Xiehe Cytogenetic Engineering Co., Ltd. on the subsidiary signing of a supplementary agreement to the “Entrusted R&D Service Contract”
Announcement of Zhongyuan Xiehe Cytogenetic Engineering Co., Ltd. on obtaining a notice of acceptance of the wholly-owned subsidiary\'s drug clinical trial application
Zhongyuan Xiehe: Legal Opinion of Beijing Guofeng Law Firm on the 2024 First Extraordinary General Meeting of Shareholders of Zhongyuan Xiehe Cell Genetic Engineering Co., Ltd.
Zhongyuan Xiehe: Announcement of Resolutions of the 2024 First Extraordinary General Meeting of Shareholders of Zhongyuan Xiehe Cytogenetic Engineering Co., Ltd.